oral glp-1 agonist approved Lesson: Semaglutide: A New Receptor Product for the Treatment of Type 2 Diabetes Orforglipron, approved as Foundayo on

Conclusions In summary, the results of this large active comparator, new user cohort study indicate that GLP-1 receptor agonists are not associated with an increased risk of suicidal ideation, self-harm, and suicide when compared with DPP-4 inhibitors or SGLT-2 inhibitors among patients with type 2 diabetes

10.1016/j.physbeh.2014.02.026 [DOI] [PubMed] [Google Scholar] Anderberg R

Carel W

A tight interplay between these two is a common finding in many patients, and many metabolic pathways show their close pathophysiological connection

CREB-mediated generation and neuronal growth regulates the behavioral improvement of geniposide in diabetes-associated depression mouse model

Cancer statistics, 2025